Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts
As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 6,253,467 | $10,130,617 | 0.02% | |
| 2. | Sio Capital Michael Castor | 1,954,715 | $3,166,638 | -10% | 0.45% |
| 3. | DAFNA Capital Management Nathan Fischel | 1,567,561 | $2,539,449 | 0.58% | |
| 4. | Kynam Capital Derrick Tang | 1,566,317 | $2,537,434 | 0.16% | |
| 5. | Ikarian Capital Neil Shahrestani | 1,492,229 | $2,417,411 | 0.2% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,467,149 | $8,856,781 | 1.84% | |
| 2. | 3,316,965 | $5,373,483 | 0.01% | |
| 3. | 2,454,278 | $3,975,930 | 0.21% | |
| 4. | 1,299,775 | $2,105,635 | 0% | |
| 5. | 620,000 | $1,004,000 | 0% |